Kanamycin sulfate

Base Information

• Chemical Name: Kanamycin sulfate
• CAS No.: 70560-51-9
• Deprecated CAS: 11030-21-0,133-92-6,11033-61-7
• Molecular Formula: C18H38N4O15S
• Molecular Weight: 582.58
• Hs Code.: 2941902000
• European Community (EC) Number: 246-933-9,223-347-1,684-844-0
• UNII: J80EX28SMQ
• DSSTox Substance ID: DTXSID1047524
• Wikidata: Q27107073
• NCI Thesaurus Code: C76152
• RXCUI: 1300476
• Metabolomics Workbench ID: 53239
• ChEMBL ID: CHEMBL1446
• Mol file: 70560-51-9.mol

Synonyms:Kanamycin;Kanamycin A;Kanamycin Sulfate;Kantrex

Chemical Property of Kanamycin sulfate

Chemical Property:

• Appearance/Colour: Off-white powder
• Melting Point: 250oC
• Boiling Point: 943.2 °C at 760 mmHg
• Flash Point: 524.2 °C
• PSA: 365.59000
• LogP: -4.06220
• Storage Temp.: 2-8°C
• Solubility.: H2O: 10-50 mg/mL As a stock solution. Stock solutions shoul
• Hydrogen Bond Donor Count: 13
• Hydrogen Bond Acceptor Count: 19
• Rotatable Bond Count: 6
• Exact Mass: 582.20543769
• Heavy Atom Count: 38
• Complexity: 720

Purity/Quality:

99% ^*data from raw suppliers

Kanamycin Sulfate ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xi; T
• Hazard Codes: Xi,T
• Statements: 61
• Safety Statements: 22-24/25-53-45-36/37/39

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)O)O)OC3C(C(C(C(O3)CO)O)N)O)N.OS(=O)(=O)O
• Isomeric SMILES: C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N.OS(=O)(=O)O
• Uses: Kanamycin Sulfate is an aminoglycoside-antibiotic with broad antibacterial spectrum.
• Therapeutic Function: Antibacterial
• Clinical Use: Kanamycin Sulfate was isolated in 1957 by Umezawaand coworkers from Streptomyces kanamyceticus. Its activityagainst mycobacteria and many intestinal bacteria, aswell as several pathogens that show resistance to other antibiotics,brought a great deal of attention to this antibiotic.As a result, kanamycin was tested and released for medicaluse in a very short time. The use of kanamycin in the United States usually is restrictedto infections of the intestinal tract (e.g., bacillarydysentery) and to systemic infections arising from Gramnegativebacilli (e.g., Klebsiella, Proteus, Enterobacter, andSerratia spp.) that have developed resistance to other antibiotics.It has also been recommended for preoperative antisepsisof the bowel. It is absorbed poorly from the intestinaltract; consequently, systemic infections must be treated byintramuscular or (for serious infections) intravenous injections.These injections are rather painful, and the concomitantuse of a local anesthetic is indicated. The use ofkanamycin in the treatment of TB has not been widely advocatedsince the discovery that mycobacteria develop resistancevery rapidly. In fact, both clinical experience andexperimental work indicate that kanamycin developscross-resistance in the tubercle bacilli with dihydrostreptomycin,viomycin, and other antitubercular drugs. Like streptomycin,kanamycin may cause decreased or complete lossof hearing. On development of such symptoms, its useshould be stopped immediately.